Joshua Lev Sells 2,166 Shares of electroCore (NASDAQ:ECOR) Stock

electroCore, Inc. (NASDAQ:ECOR) CFO Joshua Lev sold 2,166 shares of electroCore stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $6.18, for a total value of $13,385.88. Following the sale, the chief financial officer directly owned 23,667 shares of the company’s stock, valued at $146,262.06. This trade represents a 8.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

electroCore Stock Down 1.9%

Shares of NASDAQ:ECOR traded down $0.11 during trading on Friday, hitting $5.60. 38,477 shares of the stock traded hands, compared to its average volume of 112,634. The company has a market cap of $44.80 million, a price-to-earnings ratio of -3.27 and a beta of 0.30. electroCore, Inc. has a 52-week low of $4.16 and a 52-week high of $19.49. The company has a fifty day moving average price of $5.10 and a two-hundred day moving average price of $5.58.

electroCore (NASDAQ:ECOR) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.07). electroCore had a negative return on equity of 447.87% and a negative net margin of 47.46%.The firm had revenue of $8.69 million during the quarter, compared to analyst estimates of $7.84 million. electroCore has set its FY 2025 guidance at EPS. On average, equities research analysts predict that electroCore, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Wall Street Zen upgraded shares of electroCore from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of electroCore in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, electroCore presently has an average rating of “Hold” and a consensus target price of $25.50.

Institutional Trading of electroCore

Institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Investments LP boosted its holdings in shares of electroCore by 20.8% in the 3rd quarter. Two Sigma Investments LP now owns 24,603 shares of the company’s stock valued at $122,000 after buying an additional 4,231 shares during the period. Jaffetilchin Investment Partners LLC boosted its position in shares of electroCore by 26.7% in the 2nd quarter. Jaffetilchin Investment Partners LLC now owns 41,783 shares of the company’s stock valued at $221,000 after purchasing an additional 8,800 shares during the period. International Assets Investment Management LLC lifted its position in shares of electroCore by 65.7% in the 2nd quarter. International Assets Investment Management LLC now owns 77,020 shares of the company’s stock valued at $407,000 after acquiring an additional 30,550 shares in the last quarter. Jane Street Group LLC boosted its position in electroCore by 114.4% during the 1st quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock worth $246,000 after acquiring an additional 19,599 shares during the period. Finally, NewEdge Advisors LLC lifted its position in electroCore by 857.9% in the 1st quarter. NewEdge Advisors LLC now owns 161,955 shares of the company’s stock worth $1,083,000 after buying an additional 145,047 shares in the last quarter. 26.74% of the stock is owned by institutional investors and hedge funds.

About electroCore

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.